Activity: Attending an event › Organisation or participation in workshops, courses, or seminars
For 2 decades proteomics has promised a revolution in biomarker discovery. While there have been numerous studies describing newly discovered biomarkers, few have become approved for diagnostics. Arguably instrumentation and methodology has only now become sufficiently advanced to realize proteomics-based biomarker discovery in practice. The significant interpersonal variability, that affects biomarker discovery by adding a considerable amount of noise, makes it necessary to significantly increase the throughput of proteomics experiments when using primary human specimens. This talk describes a new clinical proteomics platform featuring novel 96-well plate-based sample preparation and data acquisition methods to enable the throughput needed for meaningful biomarker discovery. Example applications range from urine proteomics studies compatible with minuscule urine samples from preemies in the neonatal intensive care unit to neuroproteomics on brain specimens from patients with various forms of neurodegeneration, which lead to a new diagnostic paradigm and resulted in the identification of potential targets for immunotherapeutic strategies against e.g. Alzheimer’s disease.